Nutriband Secures Macao Patent for Innovative Drug Technology
Nutriband’s Patent Achievement in Macao
Nutriband Inc. (NASDAQ:NTRB) is thrilled to announce a significant milestone with the granting of its patent for the innovative AVERSA™ abuse-deterrent transdermal technology in Macao. This recent development underscores Nutriband's commitment to the advancement of prescription transdermal pharmaceutical products, which aim to minimize drug abuse and misuse.
Understanding the AVERSA™ Technology
The AVERSA™ technology integrates aversive agents into transdermal patches, which are designed to prevent the misuse, diversion, and accidental exposure of drugs that have a high potential for abuse, including opioids and stimulants. Notably, this technology seeks to improve patient safety while ensuring that essential medications remain accessible to individuals in need.
Broad International Patent Coverage
The granted patent in Macao is part of an extensive international intellectual property portfolio that includes patents in 46 countries around the world, covering regions such as the United States, Europe, Japan, and Australia. This robust protection demonstrates Nutriband's strategic efforts to safeguard its innovations in multiple jurisdictions.
The Role of Kindeva Drug Delivery
To advance its product offerings, Nutriband is collaborating with Kindeva Drug Delivery, a reputable global leader in contract development and manufacturing focused on drug-device combination products. Together, they are working on the AVERSA™ Fentanyl patch, which represents a step forward in providing a safer alternative for patients requiring transdermal fentanyl treatment.
Potential Impact on the Market
The AVERSA Fentanyl patch aims to become the world's first abuse-deterrent opioid patch, designed not only to mitigate risks of misuse but also to significantly reduce accidental exposure. With expectations of achieving peak annual sales in the range of $80 million to $200 million, this innovative approach could transform the landscape of opioid management and safety.
About Nutriband Inc.
Nutriband is committed to creating a diverse portfolio of products focused on transdermal delivery systems. The company is pioneering solutions that integrate abuse-deterrent technology to revolutionize how patients receive treatment, with a particular focus on safety and accessibility.
The Importance of Innovation
The growing concern over opioid misuse and abuse highlights the urgent need for effective deterrent technologies like AVERSA™. Nutriband is at the forefront of addressing this critical issue, working diligently to bring safer drug delivery systems to the market while maintaining the necessary therapeutic effectiveness.
Community Engagement and Support
Nutriband remains dedicated to transparency and engagement as it progresses. For those looking to learn more or reach out for support, the company ensures its lines of communication are open. Interested parties can connect via their official communication channels.
Frequently Asked Questions
What is the AVERSA™ technology?
The AVERSA™ technology is a transdermal system designed to prevent the abuse and misuse of medications by incorporating aversive agents that deter illicit use.
Which regions have granted patents for AVERSA™?
Nutriband's AVERSA™ technology is patented in numerous regions, including the United States, Europe, Japan, Korea, and now Macao, making it a globally recognized innovation.
What are the expected benefits of the AVERSA Fentanyl patch?
The AVERSA Fentanyl patch is designed to deter misuse and reduce accidental exposure while ensuring that patients who require fentanyl have access to it safely.
Who is Nutriband collaborating with for its product development?
Nutriband is collaborating with Kindeva Drug Delivery, a leading organization specializing in drug-device combinations, to develop the AVERSA Fentanyl patch.
How can I contact Nutriband for more information?
For inquiries, individuals can reach out via phone at 407-377-6695 or email at Support@nutriband.com.
About The Author
Contact Lucas Young privately here. Or send an email with ATTN: Lucas Young as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.